Literature DB >> 30517878

Cervical cancer cell lines are sensitive to sub-erythemal UV exposure.

Wenyi Gu1, Surong Sun2, Andrew Kahn3, Dalton Dacus3, Sebastian O Wendel3, Nigel McMillan4, Nicholas A Wallace5.   

Abstract

High risk human papillomavirus (HPV) infections are the causative agent in virtually every cervical cancer as well as a host of other anogenital and oropharyngeal malignancies. These viruses must activate DNA repair pathways to facilitate their replication, while avoiding the cell cycle arrest and apoptosis that can accompany DNA damage. HPV oncoproteins facilitate each of these goals, but also reduce genome stability. Our data dissect the cytotoxic and cytoprotective characteristics of HPV oncogenes in cervical cancer cells. These data show that while the transformation of keratinocytes by HPV oncogene leaves these cells more sensitive to UV, the oncogenes also protect against UV-induced apoptosis. Cisplatin and UV resistant cervical cancer cell lines were generated and probed for their sensitivity to genotoxic agents. Cervical cancer cells can acquire resistance to one DNA crosslinking agent (UV or cisplatin) without gaining broad tolerance of crosslinked DNA. Further, cisplatin resistance may or may not result in sensitivity to PARP1 inhibition.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Cisplatin; DNA repair; Drug resistance; Genomic instability; HPV E6; HPV E7; Human papillomavirus; UV damage

Mesh:

Substances:

Year:  2018        PMID: 30517878     DOI: 10.1016/j.gene.2018.11.079

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  2 in total

1.  Different Genotype Distribution of Human Papillomavirus between Cervical and Esophageal Cancers: A Study in Both High-Incidence Areas, Xinjiang, China.

Authors:  Yi Zheng; Yage Fan; Yan Zeng; Shiyu Liu; Limin Gao
Journal:  Biomed Res Int       Date:  2020-12-02       Impact factor: 3.411

Review 2.  Biological and clinical aspects of HPV-related cancers.

Authors:  Klaudia Anna Szymonowicz; Junjie Chen
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.